Loading...
XKRX
326030
Market cap4.17bUSD
Jul 10, Last price  
82,400.00KRW
1D
2.74%
1Q
-16.35%
IPO
-50.06%
Name

SK Biopharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XKRX:326030 chart
P/E
24.17
P/S
9.13
EPS
3,408.75
Div Yield, %
—
Shrs. gr., 5y
1.76%
Rev. gr., 5y
93.58%
Revenues
706.74b
+29.06%
37,631,486,14051,798,062,83060,454,791,13072,440,821,40071,416,701,94089,927,545,43085,316,069,9501,098,738,190123,852,416,02025,999,027,000418,644,529,000246,179,120,000354,891,556,000547,596,283,000706,740,960,000
Net income
266.95b
+10.89%
-19,465,137,000-30,330,598,000-41,001,914,000-37,048,875,000-28,061,186,000-30,360,843,000-97,649,060,000-138,096,479,000-71,519,466,820-247,413,614,00064,845,640,000-139,430,878,000-32,882,849,000240,738,038,000266,950,498,000
CFO
180.53b
+90.24%
-16,962,588,800-24,065,043,200-39,064,435,900-40,336,395,590-28,716,692,010-48,941,251,590-98,342,730,340-141,281,399,300-81,334,671,550-210,726,009,000-92,871,733,000-159,920,062,000-94,201,249,00094,899,993,000180,534,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
URL
https://www.skbp.com/
IPO date
Jul 02, 2020
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT